Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neuronetics, Inc. (NASDAQ: STIM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Neuronetics is a commercial stage medical technology and healthcare company focused on NeuroStar Advanced Therapy, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment, and on operating Greenbrook TMS treatment centers across the United States. Its filings offer detailed insight into how this device-and-clinic model is reflected in reported revenues, capital structure, and risk disclosures.
Among the most relevant documents for STIM are current reports on Form 8-K, which Neuronetics uses to announce quarterly financial and operating results, amendments to its credit agreement with Perceptive Credit Holdings IV, LP, and other material events. These filings confirm that the company’s common stock is listed on The Nasdaq Global Market and provide information on revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue from Greenbrook centers. Form 8-Ks also describe leadership changes, such as the appointment of a new Chief Financial Officer and a planned CEO retirement, and summarize key terms of executive employment and compensation arrangements.
Investors reviewing Neuronetics’ filings can also examine disclosures about its credit facility, including additional borrowing tranches, minimum liquidity requirements, and associated warrant issuances. Safe harbor statements in these reports outline forward-looking risks related to reliance on NeuroStar Advanced Therapy System sales and usage, payer coverage and reimbursement for TMS treatments, competition from other technologies, and the integration of Greenbrook’s clinic business.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. Users can quickly see how Neuronetics presents its business model, revenue drivers, and risk factors, and can also track insider and equity-related activity through filings that describe inducement equity awards and warrant issuances. Real-time updates from EDGAR ensure that new Neuronetics filings, including financial results and material agreements, are available promptly with simplified explanations for faster analysis.
Neuronetics, Inc. President and CEO Keith J. Sullivan reported an open-market sale of 8,452 shares of common stock at a reported weighted average price of $1.35 per share. According to the filing, these were non-discretionary sales to satisfy tax withholding obligations upon vesting of a restricted stock unit award. After the transaction, Sullivan directly owned 1,524,713 shares of Neuronetics common stock.
Keith Sullivan reported insider sales of common stock. The filing lists 8,452 shares classified as securities to be sold following 02/24/2026 vesting as compensation. The filing also discloses sales of 40,976 shares on 02/10/2026 and 33,847 shares on 02/12/2026, with dollar amounts shown alongside each sale.
STIM files a Form 144 notice to sell Common shares. The notice lists 3,427 shares under "Securities To Be Sold" tied to Restricted Stock Vesting on 02/24/2026. The filing also reports prior sales by William A. Macan of 3,485 shares on 02/10/2026 and 14,120 shares on 02/12/2026.
Neuronetics, Inc. reported that its Board and Compensation Committee approved annual cash incentive awards for three senior executives. On February 23, 2026, the Compensation Committee approved cash incentives of $73,216.44 for Executive Vice President and Chief Financial Officer Steven E. Pfanstiel and $163,383.75 for Executive Vice President, Chief Legal Officer, and Corporate Secretary W. Andrew Macan.
On the same date, the Board, following the Compensation Committee’s recommendation, approved an annual cash incentive award of $412,775.95 for President and Chief Executive Officer Keith J. Sullivan. The company stated that these cash incentive awards will be paid on or about March 13, 2026.
Neuronetics, Inc. reported that EVP, CFO and Treasurer Steven Pfanstiel acquired an award of 250,000 shares of common stock in the form of restricted stock units. The award was granted at no purchase price.
The RSUs vest in three equal annual installments beginning on February 23, 2027, as long as he remains in continuous service through each vesting date. After this grant, his directly held common stock position reported in the filing totals 820,212 shares.
Neuronetics, Inc. reported that executive vice president, chief legal officer and corporate secretary William Andrew Macan acquired 210,000 restricted stock units (RSUs) of common stock as an equity award. Each RSU represents the right to receive one Neuronetics common share.
The RSU award vests in three equal annual installments beginning on February 23, 2027, subject to Mr. Macan’s continuous service through each vesting date. Following this grant, he directly holds 883,561 shares of Neuronetics common stock. This is a non-cash, stock-based compensation grant rather than an open‑market purchase.
Neuronetics, Inc. director and CEO Keith J. Sullivan reported an open-market sale of 33,847 shares of common stock at a weighted average price of $1.65 per share. After this transaction, he directly holds 1,533,165 shares of Neuronetics common stock.
According to the footnotes, these were non-discretionary sales made solely to satisfy the reporting person's tax withholding obligation upon vesting of a restricted stock unit award. The shares were sold in multiple trades at prices ranging from $1.56 to $1.72 per share.
Neuronetics, Inc. executive William Andrew Macan reported an open-market sale of 14,120 shares of common stock at a weighted average price of $1.65 per share on February 12, 2026. According to the disclosure, these were non-discretionary sales made solely to cover tax withholding obligations triggered by the vesting of a restricted stock unit award.
After this transaction, Macan beneficially owned 673,561 shares of Neuronetics common stock directly. The price range for the individual trades was between $1.56 and $1.72 per share, with the insider indicating that detailed trade breakdowns are available upon request.
Neuronetics, Inc. executive William Andrew Macan, EVP, CLO and CS, reported selling 3,485 shares of common stock on February 10, 2026. The Form 4 notes these were non-discretionary sales made solely to satisfy tax withholding on the vesting of a restricted stock unit award, at a weighted average price of $1.55 per share. After this transaction, Macan directly beneficially owned 687,681 shares of Neuronetics common stock.
Neuronetics, Inc. President and CEO Keith J. Sullivan reported an open-market sale of 40,976 shares of common stock on February 10, 2026 at a weighted average price of $1.55 per share. According to the disclosure, these were non-discretionary sales made solely to satisfy his tax withholding obligation upon the vesting of a portion of a restricted stock unit award.
After this transaction, Sullivan directly beneficially owned 1,567,012 shares of Neuronetics common stock.